Frontiers in ophthalmologyPub Date : 2026-09-17eCollection Date: 2026-01-01DOI: 10.3389/fopht.2026.1718017
Terry Henry, Grace Staes, Alexius Russell, Nikisha Q Richards-Walker
{"title":"Accuracy, readability, and bias of GPT-4o mini responses to oculoplastic patient questions.","authors":"Terry Henry, Grace Staes, Alexius Russell, Nikisha Q Richards-Walker","doi":"10.3389/fopht.2026.1718017","DOIUrl":"https://doi.org/10.3389/fopht.2026.1718017","url":null,"abstract":"<p><strong>Purpose: </strong>This cross-sectional evaluation of model outputs evaluates the accuracy, readability, transparency, objectivity, completeness, and bias of GPT-4o mini responses to common oculoplastic patient questions.</p><p><strong>Methods: </strong>The study was reviewed and deemed exempt from institutional review board approval. Thirty-three questions were developed across eight clinical domains: floppy eyelid syndrome, cicatricial ectropion, entropion, blepharoplasty, facial aging, brow lift, ptosis, and facial nerve function. Seven domains contained four patient-centered questions, while the facial aging domain contained five questions, for a total of 33 questions. On September 16, 2024, GPT-4o mini was prompted for each question with a standardized prompt requesting responses from the perspective of an expert oculofacial surgeon, using the latest medical guidelines. Verbatim responses were recorded. Six American Society of Ophthalmic Plastic and Reconstructive Surgery fellowship-trained surgeons independently evaluated each response using a 5-point Likert scale assessing clinical accuracy, completeness, transparency, objectivity, and bias. Readability was assessed using established readability indices.</p><p><strong>Results: </strong>GPT-4o mini demonstrated moderate clinical accuracy and completeness. Clinical accuracy was rated favorably in 51% of ratings (101/198), while completeness was rated favorably in 42% (84/198). Transparency and objectivity demonstrated stronger performance. 78% of ratings (155/198) agreed or strongly agreed that responses were transparent and 76% of ratings (150/198) agreed or strongly agreed that responses were objective. 8% of ratings (16/198) agreed or strongly agreed that Bias was present, while 65% (129/198) disagreed or strongly disagreed. Readability analyses demonstrated that ratings required college- to graduate-level reading ability.</p><p><strong>Conclusion: </strong>GPT-4o mini generated transparent and objective ratings with low measured bias but demonstrated limitations in clinical accuracy, completeness, and readability. These findings apply specifically to GPT-4o mini and should not be generalized to other large language models. Future investigations should compare contemporary language models, evaluate alternative prompting strategies, and investigate multimodal systems that integrate text, clinical photographs, periocular anatomy, and patient symptoms.</p>","PeriodicalId":73096,"journal":{"name":"Frontiers in ophthalmology","volume":"6 ","pages":"1718017"},"PeriodicalIF":2.4,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13626896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149119301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in ophthalmologyPub Date : 2026-09-17eCollection Date: 2026-01-01DOI: 10.3389/fopht.2026.1924390
Mazyar Yazdani
{"title":"Emerging mechanisms in dry eye disease: apoptosis-associated tear MicroRNAs and toxicant-related alterations of the glycocalyx and lipid rafts.","authors":"Mazyar Yazdani","doi":"10.3389/fopht.2026.1924390","DOIUrl":"https://doi.org/10.3389/fopht.2026.1924390","url":null,"abstract":"<p><strong>Background: </strong>Dry eye disease (DED), a multifactorial condition of the ocular surface, is marked by disruption of tear film homeostasis that can result in ocular discomfort, visual impairment, and potential epithelial damage. Its high prevalence and impact on quality of life and healthcare utilization underscore the need to better understand its underlying mechanisms. Although current research has clarified several key contributors, including tear film instability, ocular surface inflammation, and neural dysfunction, the complex pathophysiology of DED remains only partly understood. Moreover, new mechanistic insights are needed to advance diagnostic and therapeutic approaches.</p><p><strong>Hypothesis: </strong>This article highlights three emerging and underexplored mechanisms that may contribute to DED, based on a combination of disease-associated observations, indirect evidence, and mechanistic inference: (i) apoptosis-related tear microRNAs (miRNAs) as potential regulators of epithelial damage, (ii) ocular surface glycocalyx alterations potentially associated with environmental pollutants, and (iii) lipid raft disruption as a plausible mediator of toxicant-induced responses in ocular surface cells.</p><p><strong>Supporting evidence: </strong>First, apoptosis-related miRNAs in tears, traditionally viewed as potential biomarkers of the disease, are discussed as candidate regulators of epithelial damage through modulation of apoptotic pathways, although direct evidence in DED causation/development remains limited. Second, glycocalyx alterations potentially associated with environmental pollutants, such as airborne nanoparticles and reactive volatile compounds, are considered. This consideration draws in part on findings from non-ocular and non-DED systems. Third, lipid raft disruption is presented as a plausible but as yet untested mechanism in the context of the ocular surface and DED, potentially linking toxicant exposure to downstream cellular responses.</p><p><strong>Conclusion: </strong>By distinguishing between established knowledge, disease-associated findings, and forward-looking hypotheses, this work aims to broaden current perspectives on DED pathophysiology and suggest novel directions for future research.</p>","PeriodicalId":73096,"journal":{"name":"Frontiers in ophthalmology","volume":"6 ","pages":"1924390"},"PeriodicalIF":2.4,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13627036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149119406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Analysis of clinical factors affecting corneal endothelial cell density in eye bank donors.","authors":"Lan Yu, Wei Ming, Shangcao Wu, Qiaoqiao Dong, Jingwei Li, Jiao Qin, Qingyan Zeng","doi":"10.3389/fopht.2026.1952825","DOIUrl":"https://doi.org/10.3389/fopht.2026.1952825","url":null,"abstract":"<p><strong>Purpose: </strong>To systematically analyze factors influencing corneal endothelial cell density (ECD) in eye bank donors and provide robust evidence for optimizing donor screening strategies.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 1438 corneas from 782 donors (2013-2025). Associations between ECD and donor age, sex, laterality, cause and season of death, cataract surgery, cancer, Diabetes Mellitus (DM), and death-to-preservation time (DTP) were evaluated using univariate analysis and a generalized linear mixed model (GLMM).</p><p><strong>Results: </strong>Univariate analysis showed ECD was significantly associated with age, cataract surgery, DTP, cause of death, and death season (all <i>P</i> < 0.05). The GLMM indicated that age, cataract surgery, and DTP were highly significant independent predictors (all <i>P</i> < 0.001): ECD was 287.737 cells/mm² higher in donors without cataract surgery (95% CI: 177.109-398.365), and decreased by 3.847 cells/mm² (95% CI: -5.561 to -2.134) per year of age and 18.342 cells/mm² (95% CI: -27.623 to -9.062) per hour increase in preservation time. Among causes of death, only the cardiovascular/cerebrovascular disease group differed significantly from the chronic organ failure group (<i>P</i> = 0.013); other factors including sex, eye laterality, cancer, DM, and death season showed no independent effects (all <i>P</i>>0.05).</p><p><strong>Conclusion: </strong>Advanced age, prior cataract surgery, and prolonged death-to-preservation time were independently associated with lower ECD. Cause of death was not an independent predictor overall, although donors who died from CCVDs had significantly higher ECD than those with chronic organ failure. These findings provide a robust evidence base for clinical donor screening and allocation, thereby maximizing the utility of scarce donor corneas.</p>","PeriodicalId":73096,"journal":{"name":"Frontiers in ophthalmology","volume":"6 ","pages":"1952825"},"PeriodicalIF":2.4,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13623622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149119245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Artificial intelligence in corneal endothelial disease and endothelial keratoplasty: current evidence, clinical readiness, and future directions.","authors":"Anđela Jukić, Kata Čulina, Vedran Markušić, Sanja Masnec, Suzana Matić, Miro Kalauz","doi":"10.3389/fopht.2026.1951354","DOIUrl":"10.3389/fopht.2026.1951354","url":null,"abstract":"<p><p>Corneal endothelial disease generates high-dimensional imaging and longitudinal data, making it well suited to artificial intelligence (AI). This review follows AI across the endothelial care pathway and judges each application by translational maturity rather than discrimination alone, drawing on a targeted PubMed/MEDLINE search of studies published between 2011 and July 2026. Technical performance is strongest when the task is measurement against a reproducible human reference: endothelial cell segmentation, image quality control, edema and pachymetric mapping, and quantification of Descemet membrane endothelial keratoplasty (DMEK) detachment. However, performance declines as tasks become prognostic or when models cross devices, surgeons, and centers. External validation reduced the area under the curve from 0.96 to 0.77 in one Fuchs endothelial corneal dystrophy (FECD) detection model, and a 2025 systematic review identified external validation in only three of 19 FECD studies. Calibration, uncertainty quantification, decision curve analysis, and prospective human-AI comparison remain uncommon. The most mature applications are therefore measurement and quality-control tasks, including automated donor endothelial cell density assessment in eye banking. FECD staging, prediction of decompensation after cataract surgery, the need for rebubbling (reinjection of air or gas into the anterior chamber to promote graft reattachment), rejection, and long-term graft survival remain investigational. By covering the full clinical pathway together with eye banking, regenerative therapies, foundation models, language models, an explicit clinical-readiness framework, and the European regulatory context, this review outlines the current requirements for clinical translation: multicenter external validation, transparent reporting, safe abstention, and prospective clinical impact studies.</p>","PeriodicalId":73096,"journal":{"name":"Frontiers in ophthalmology","volume":"6 ","pages":"1951354"},"PeriodicalIF":2.4,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13620467/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149082925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in ophthalmologyPub Date : 2026-09-15eCollection Date: 2026-01-01DOI: 10.3389/fopht.2026.1976103
Ahmed M Sayed, Nasif Zaman, Padmaja Kumari Rani
{"title":"Editorial: Telemedicine in ophthalmology: cost-effectiveness and barriers to widespread adoption.","authors":"Ahmed M Sayed, Nasif Zaman, Padmaja Kumari Rani","doi":"10.3389/fopht.2026.1976103","DOIUrl":"https://doi.org/10.3389/fopht.2026.1976103","url":null,"abstract":"","PeriodicalId":73096,"journal":{"name":"Frontiers in ophthalmology","volume":"6 ","pages":"1976103"},"PeriodicalIF":2.4,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13619488/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149082833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in ophthalmologyPub Date : 2026-09-14eCollection Date: 2026-01-01DOI: 10.3389/fopht.2026.1949916
Michael Wormstone
{"title":"Global challenges for lens and cataract research.","authors":"Michael Wormstone","doi":"10.3389/fopht.2026.1949916","DOIUrl":"10.3389/fopht.2026.1949916","url":null,"abstract":"<p><p>The lens is sadly too often dismissed as a less important tissue within the eye, but this neglects to appreciate the role it plays in the wellbeing and quality of life of individuals, the economic burden lens pathologies place on society and the true biological wonder it is! A normal healthy lens in isolation, looks like a jewel, formed from biological glass. The lens is made of cells enveloped in a soft collagen shell. No blood supply, no nerves. There is slow cell growth that occurs progressively over a lifetime and little cell death takes place. Furthermore, the lens is not a static system and has to quite literally accommodate and manage ongoing mechanical changes due to shape-changing accommodation. Despite these challenges, lens cells are orchestrated to perfect harmony to generate an anatomy conducive to transparency, refraction and accommodation. Pathologies of the lens compromise wellbeing. Congenital and early onset cataract can lead to blindness in tens of thousands of people, while in later life age-related cataracts lead to visual deterioration and blindness in tens of millions. The only treatment for cataract is surgery with intraocular lens (IOL) implantation. Cataract surgery is the most common operation in the world and IOLs the most common medical implant. Despite the success of cataract surgery, wound-healing responses lead to secondary visual loss, known as posterior capsule opacification, in approximately 20% of patients. This can be resolved by Nd: YAG Capsulotomy, but this is not without risk; this is the second most common operation in the world. In addition, presbyopia commonly present in middle age and affects billions, impacting personal wellbeing and ability to perform specific roles. Collectively, these conditions compromise individuals and place significant financial burdens on healthcare providers. The need to undertake lens and cataract research therefore remains a key health priority. As a community the lens field faces both medical and political challenges that need to be considered, appreciated and addressed. In the current article the lens and cataract research landscape is assessed and evaluated with potential strategies proposed to build on existing strengths and address areas of underused potential to continue advancing knowledge and impact on the health and wellbeing of millions and potentially billions of patients.</p>","PeriodicalId":73096,"journal":{"name":"Frontiers in ophthalmology","volume":"6 ","pages":"1949916"},"PeriodicalIF":2.4,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13616652/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149076938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Editorial: Interventional modalities for the prevention and management of childhood myopia.","authors":"Rohit Saxena, Vinay Gupta, Meghal Gagrani, Jaspreet Sukhija","doi":"10.3389/fopht.2026.1941158","DOIUrl":"10.3389/fopht.2026.1941158","url":null,"abstract":"","PeriodicalId":73096,"journal":{"name":"Frontiers in ophthalmology","volume":"6 ","pages":"1941158"},"PeriodicalIF":2.4,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13590290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149018980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in ophthalmologyPub Date : 2026-09-01eCollection Date: 2026-01-01DOI: 10.3389/fopht.2026.1675048
Anindya Samanta, Chelsey Krambeer, Addie Flowers, Matthew Porter
{"title":"Selective laser trabeculoplasty for anti-VEGF associated intraocular pressure elevation in steroid-naïve eyes.","authors":"Anindya Samanta, Chelsey Krambeer, Addie Flowers, Matthew Porter","doi":"10.3389/fopht.2026.1675048","DOIUrl":"10.3389/fopht.2026.1675048","url":null,"abstract":"<p><strong>Purpose: </strong>Selective Laser Trabeculoplasty (SLT) is utilized in cases of primary and certain secondary open-angle glaucoma to decrease intraocular pressure (IOP). SLT effectiveness has been demonstrated in patients with increased IOP secondary to intraocular steroids. In addition to intravitreal steroids, intravitreal anti-vascular endothelial growth factor (VEGF) injections are commonly used in patients with diabetic retinopathy and age-related macular degeneration. Some patients receiving anti-VEGF injections experience increases in IOP. No studies have evaluated the effectiveness of SLT for anti-VEGF-associated glaucoma.</p><p><strong>Methods: </strong>This was a retrospective, single-center study. Anti-VEGF-associated IOP increase was defined as an eye receiving at least one anti-VEGF intravitreal injection prior to SLT. IOP and the number of pressure-lowering drops were measured at 3-, 6-, 9-, and 12-month post-SLT follow-up appointments. Outcomes included changes in IOP, and the number of IOP-lowering drops prescribed.</p><p><strong>Results: </strong>Twenty-three eyes from 18 patients were included in this study. The IOP was 18.26 ± 3.33 with 2.6 ± 1. drops prescribed at baseline. Two eyes required repeat SLT. Over the study period, IOP was reduced by 3 to 4.5 mm Hg, with all p-values <0.001. Eight eyes in the study were drop-naïve (no IOP-lowering drops prescribed prior to SLT). Of these, 6/8 (75%) remained drop-free at the end of the observation period. At their final clinic visit, 78.3% of patients were controlled on SLT without further surgical or medical intervention.</p><p><strong>Conclusions: </strong>To the best of our knowledge, this is the first study to demonstrate the long-term effectiveness of SLT in anti-VEGF-associated open-angle glaucoma in steroid-naïve eyes.</p>","PeriodicalId":73096,"journal":{"name":"Frontiers in ophthalmology","volume":"6 ","pages":"1675048"},"PeriodicalIF":2.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13574573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148978905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in ophthalmologyPub Date : 2026-09-01eCollection Date: 2026-01-01DOI: 10.3389/fopht.2026.1835844
Anina Zeier, Markus Tschopp, Daniel Barthelmes, Anthia Papazoglou
{"title":"Two-year outcomes of PRESERFLO MicroShunt implantation in a real-world heterogeneous glaucoma cohort: a retrospective single-center study.","authors":"Anina Zeier, Markus Tschopp, Daniel Barthelmes, Anthia Papazoglou","doi":"10.3389/fopht.2026.1835844","DOIUrl":"10.3389/fopht.2026.1835844","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate intraocular pressure (IOP), medication burden, best-corrected visual acuity (BCVA), and safety outcomes after <i>ab externo</i> PRESERFLO MicroShunt (PreserFlo) implantation in routine clinical practice.</p><p><strong>Methods: </strong>This retrospective single-center study included patients undergoing PreserFlo implantation (standalone or combined with phacoemulsification) between 2019 and 2022. IOP, BCVA, and glaucoma medications were collected preoperatively and postoperatively (day 1, week 1, month 1, year 1, and year 2). Hypotony was defined as IOP ≤ 5 mmHg. Complete success at 2 years required IOP ≤ 21 mmHg with ≥20% reduction from baseline without glaucoma medication.</p><p><strong>Results: </strong>Eighty-one eyes of 74 patients (mean age 73.2 years) were included. Mean baseline IOP was 24.0 ± 10.2 mmHg, decreasing to 12.5 ± 3.8 mmHg at year 1 (p < 0.0001) and 13.5 ± 3.4 mmHg at year 2 (p = 0.0005). Mean BCVA was 0.63 ± 0.30 at baseline, 0.70 ± 0.31 at year 1, and 0.73 ± 0.27 at year 2, indicating stable visual acuity during follow-up. Mean IOP reduction was 39.6% at year 1 and 33.8% at year 2; 75.6% and 73.3% achieved ≥20% IOP reduction at years 1 and 2, respectively. Medications decreased from 3.09 ± 1.02 to 0.44 ± 0.97 (year 1) and 0.45 ± 0.85 (year 2), and their medication-free rates were 80.5% and 73.3%, respectively. Complications occurred in 55.6% of eyes; 27.2% required postoperative interventions (needling 20.9%); 15.0% required further glaucoma surgery. Complete success rates were 60.2% (year 1) and 52.0% (year 2).</p><p><strong>Conclusions: </strong>PreserFlo implantation provided sustained mid-term IOP reduction with substantial medication sparing and stable BCVA.</p>","PeriodicalId":73096,"journal":{"name":"Frontiers in ophthalmology","volume":"6 ","pages":"1835844"},"PeriodicalIF":2.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13574660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148978852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in ophthalmologyPub Date : 2026-08-25eCollection Date: 2026-01-01DOI: 10.3389/fopht.2026.1892069
Hamad M Alsulaiman, Huda AlGhadeer
{"title":"Corneal neurotization for neurotrophic keratopathy: a case report of two patients from different age groups.","authors":"Hamad M Alsulaiman, Huda AlGhadeer","doi":"10.3389/fopht.2026.1892069","DOIUrl":"10.3389/fopht.2026.1892069","url":null,"abstract":"<p><strong>Purpose: </strong>To describe the techniques and the successful outcomes of corneal neurotization (CN) for the treatment of neurotrophic keratopathy (NK) in two patients from different age groups.</p><p><strong>Methods: </strong>A detailed clinical examination and comprehensive systemic workup were performed to determine the etiology of NK. Both cases were managed surgically with CN and followed for 3 years postoperatively at the King Khaled Eye Specialist Hospital & Research Center, Riyadh, Saudi Arabia.</p><p><strong>Results: </strong>Two eyes of a 66-year-old male and a 22-month-old boy who were diagnosed with NK and refractory to conservative therapy underwent CN. The first patient underwent indirect corneal neurotization for the management of NK in the right eye from the ipsilateral infraorbital nerve using a sural nerve interposition graft from the left leg, while the second patient underwent indirect corneal neurotization for the management of NK in the left eye from the contralateral right supraorbital nerve using a sural nerve interposition graft from the left leg. The symptoms improved following the procedure as well as the corneal sensation, with improvement of the NK in both patients. At the three-year follow-up, our patients showed no complications or NK recurrence.</p><p><strong>Conclusions: </strong>CN is a valuable surgical technique for the management of recalcitrant NK and possibly for restoring corneal sensation in some with NK prior to the development of irreversible stromal damage.</p>","PeriodicalId":73096,"journal":{"name":"Frontiers in ophthalmology","volume":"6 ","pages":"1892069"},"PeriodicalIF":2.4,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13549859/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148914633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}